In this issue:
Upadacitinib maintenance for moderate–severe UC
Abdominal pain in IBD in remission
New therapeutic strategies decrease colectomies in paediatric-onset UC
Patients with more visceral adipose tissue may need more infliximab to achieve remission
Real-world tofacitinib de-escalation in moderate–severe UC
Noninvasive assessment of postoperative CD recurrence
Early ultrasound predicts long-term endoscopic response to biologics in UC
Holding IBD medications for COVID-19 vaccinations
Upadacitinib improves abdominal pain, bowel urgency and fatigue in UC
Real-world ustekinumab vs. anti-TNF agents in CD
Please login below to download this issue (PDF)